NM-9405

N/A

Report date: 2025/01/26 17:30:32

Base Information

Drug NameNM-9405
Drug Alias Nameh-Yalciomab (Novelmed Therapeutics Inc)humanized Yalciomab (Novelmed Therapeutics Inc)NM-9405
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionTumor necrosis factor receptor superfamily member 1A inhibitors
TargetsTumor necrosis factor receptor superfamily member 1A
Therapy Area/IndicationsMacular DegenerationArthritis, Rheumatoid
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesNovelMed Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesNovelMed Therapeutics Inc
Inactive CompaniesN/A
Active IndicationsMacular DegenerationArthritis, Rheumatoid
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A